| Margins | Investing in energy efficiency; 3.8 Cr capital investment for efficiency. |
|---|---|
| Management confidence | High regarding sustainability goals and decarbonization journey. |
Growth
Achieved 73% reduction in carbon emissions vs FY21 base. Renewable energy share in total mix reached 63% in FY25.
Outlook
Targets carbon neutral operations by 2030 and 100% renewable power by 2030. Planned ESG risk screening for critical suppliers by FY2027.
Risks
Identified climate-related risks and water stress; 20% of freshwater requirement is sourced from water-stressed regions.
Last quarter's promises, checked
Delivered
- Guided R&D 2.5-3% of sales → delivered 2.8% (= BEAT)
- Guided EBITDA margin 25-26% → delivered 25.4% (= BEAT)
- Guided capex ~5% of revenue → delivered 5.2% (= BEAT)
Partly delivered
- Guided double-digit OTC growth → delivered 9% for FY26 (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,496.30
- Market cap
- ₹1,03,108 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.5×Sector 47.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
- Value
- ₹4.22 Cr
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma Management Change
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.